Share：
Share this content in WeChat
X
[Chinese][PDF]72688
• Review •
The research status of structural and functional imaging in Parkinson's disease with visual hallucinations
WU Xiaolin  CHENG Oumei 

Cite this article as: Wu XL, Cheng OM. The research status of structural and functional imaging in Parkinson's disease with visual hallucinations. Chin J Magn Reson Imaging, 2020, 11(3): 224-227. DOI:10.12015/issn.1674-8034.2020.03.014.


[Abstract] Parkinson's disease (PD) is a common neurodegenerative disease characterized by various motor and non-motor symptoms. Visual hallucinations are most common non-motor symptoms, which seriously affect the quality of life of PD patients, increase the hospitalization and mortality rate, and the burden of care, available data indicates that PD patients with visual hallucinations are more likely to develop cognitive impairment. However, the mechanism of PD with visual hallucinations are remain unclear. With the development of technologies, more and more structural and functional imaging research being conducted to detect the structural and functional changes in PD with visual hallucinations patients.
[Keywords] Parkinson's disease；visual hallucinations；Magnetic resonance imaging；Review

WU Xiaolin Department of Neurology, the First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China

CHENG Oumei* Department of Neurology, the First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China

*Corresponding to: Cheng OM, E-mail: chengoumei01@aliyun.com

Conflicts of interest   None.

ACKNOWLEDGMENTS  This paper is supported by the National Natural Science Foundation of China No. 81871002
Received  2019-11-08
Accepted  2020-02-12
DOI: 10.12015/issn.1674-8034.2020.03.014
Cite this article as: Wu XL, Cheng OM. The research status of structural and functional imaging in Parkinson's disease with visual hallucinations. Chin J Magn Reson Imaging, 2020, 11(3): 224-227. DOI:10.12015/issn.1674-8034.2020.03.014.

[1]
Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. J neurochem, 2016, 139(Suppl 1): 318-324.
[2]
Pfeiffer RF. Non-motor symptoms in Parkinson's disease. Parkinsonism Relat Dis, 2016, 22(Suppl 1): S119-122.
[3]
Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Movement Dis, 2007, 22(11): 1623-1629.
[4]
Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Movement Dis, 2006, 21(7): 916-923.
[5]
Guo Y, Xu W, Liu FT, et al. Modifiable risk factors for cognitive impairment in Parkinson's disease: a systematic review and meta-analysis of prospective cohort studies. Movement Dis, 2019, 34(6): 876-883.
[6]
Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci, 2010, 289(1-2): 12-17.
[7]
Gibson G, Mottram PG, Burn DJ, et al. Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson's disease: a longitudinal 4-year study. Int J Geriatr Psychiatry, 2013, 28(6): 626-631.
[8]
Gama RL, De Bruin VM, De Bruin PF, et al. Risk factors for visual hallucinations in patients with Parkinson's disease. Neurol Res, 2015, 37(2): 112-116.
[9]
Sakai K, Ikeda T, Ishida C, et al. Delusions and visual hallucinations in a patient with Parkinson's disease with dementia showing pronounced Lewy body pathology in the nucleus basalis of Meynert. Neuropathology, 2019, 39(4): 319-323.
[10]
Harding AJ, Stimson E, Henderson JM, et al. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain, 2002, 125(Pt 11): 2431-2445.
[11]
Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage, 2000, 11(6Pt 1): 805-821.
[12]
Shin S, Lee JE, Hong JY, et al. Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson's disease. J Neurol Neurosurg Psychiatry, 2012, 83(12): 1155-1161.
[13]
Watanabe H, Senda J, Kato S, et al. Cortical and subcortical brain atrophy in Parkinson's disease with visual hallucination. Movement Dis, 2013, 28(12): 1732-1736.
[14]
Gama RL, Bruin VM, Tavora DG, et al. Structural brain abnormalities in patients with Parkinson's disease with visual hallucinations: a comparative voxel-based analysis. Brain Cogn, 2014, 87: 97-103.
[15]
Firbank MJ, Parikh J, Murphy N, et al. Reduced occipital GABA in Parkinson disease with visual hallucinations. Neurology, 2018, 91(7): e675-e685.
[16]
Pezzoli S, Cagnin A, Antonini A, et al. Frontal and subcortical contribution to visual hallucinations in dementia with Lewy bodies and Parkinson's disease. Postgrad Med, 2019, 131(7): 509-522.
[17]
Hepp DH, Foncke EMJ, Berendse HW, et al. Damaged fiber tracts of the nucleus basalis of Meynert in Parkinson's disease patients with visual hallucinations. Sci Report, 2017, 7(1): 10112.
[18]
Yao N, Cheung C, Pang S, et al. Multimodal MRI of the hippocampus in Parkinson's disease with visual hallucinations. Brain Struct Funct, 2016, 221(1): 287-300.
[19]
Lee WW, Yoon EJ, Lee JY, et al. Visual hallucination and pattern of brain degeneration in Parkinson's disease. Neuro Degen Dis, 2017, 17(2-3): 63-72.
[20]
Hall JM, O'callaghan C, Muller AJ, et al. Changes in structural network topology correlate with severity of hallucinatory behavior in Parkinson's disease. Network Neurosci, 2019, 3(2): 521-538.
[21]
Lee JY, Yoon EJ, Lee WW, et al. Lateral geniculate atrophy in Parkinson's with visual hallucination: a trans-synaptic degeneration? Movement Dis, 2016, 31(4): 547-554.
[22]
Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology, 2004, 63(8): 1409-1416.
[23]
Holroyd S, Wooten GF. Preliminary FMRI evidence of visual system dysfunction in Parkinson's disease patients with visual hallucinations. J Neuropsychiatry Clin Neurosci, 2006, 18(3): 402-404.
[24]
Ramirez-Ruiz B, Marti MJ, Tolosa E, et al. Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study. Movement Dis, 2008, 23(16): 2335-2343.
[25]
Shine JM, Muller AJ, O'callaghan C, et al. Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson's disease: a task-based fMRI study. NPJ Parkinson's Dis, 2015, 1: 15003.
[26]
Yao N, Shek-Kwan Chang R, Cheung C, et al. The default mode network is disrupted in Parkinson's disease with visual hallucinations. Human Brain Mapping, 2014, 35(11): 5658-5666.
[27]
Dujardin K, Roman D, Baille G, et al. What can we learn from fMRI capture of visual hallucinations in Parkinson's disease? Brain Imaging Behav, 2019. [ DOI: ]
[28]
Hepp DH, Foncke EMJ, Olde Dubbelink KTE, et al. Loss of functional connectivity in patients with parkinson disease and visual hallucinations. Radiology, 2017, 285(3): 896-903.
[29]
Yao N, Pang S, Cheung C, et al. Resting activity in visual and corticostriatal pathways in Parkinson's disease with hallucinations. Parkinsonism Relat Diss, 2015, 21(2): 131-137.
[30]
Lewis SJ, Shine JM, Duffy S, et al. Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease. Movement Dis, 2012, 27(10): 1262-1267.
[31]
Nagano-Saito A, Washimi Y, Arahata Y, et al. Visual hallucination in Parkinson's disease with FDG PET. Movement Dis, 2004, 19(7): 801-806.
[32]
Nishio Y, Yokoi K, Hirayama K, et al. Defining visual illusions in Parkinson's disease: Kinetopsia and object misidentification illusions. Parkinsonism Relat Dis, 2018, 55: 111-116.
[33]
Gasca-Salas C, Clavero P, Garcia-Garcia D, et al. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment. Human Brain Mapping, 2016, 37(3): 968-977.
[34]
Cho SS, Strafella AP, Duff-Canning S, et al. The Relationship between serotonin-2A receptor and cognitive functions in nondemented Parkinson's disease patients with visual hallucinations. Movement Dis Clin Pract, 2017, 4(5): 698-709.
[35]
Ballanger B, Strafella AP, Van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Archiv Neurol, 2010, 67(4): 416-421.
[36]
Kiferle L, Ceravolo R, Giuntini M, et al. Caudate dopaminergic denervation and visual hallucinations: evidence from a (1)(2)(3)I-FP-CIT SPECT study. Parkinsonism Relat Dis, 2014, 20(7): 761-765.
[37]
Shine JM, Halliday GM, Naismith SL, et al. Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? Movement Dis, 2011, 26(12): 2154-2159.
[38]
Jaakkola E, Joutsa J, Makinen E, Et Al. Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson's disease. Eur J Neurol, 2017, 24(11): 1341-1347.
[39]
Matsui H, Nishinaka K, Oda M, et al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Movement Dis, 2006, 21(12): 2140-2144.
[40]
Oishi N, Udaka F, Kameyama M, et al. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology, 2005, 65(11): 1708-1715.

PREV Diffusion kurtosis imaging: research advances in brain tumors
NEXT Advances in imaging studies of senile depression
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn